Key points are not available for this paper at this time.
This review examines the impact of dexmedetomidine, an alpha-2 adrenergic receptor agonist, on postoperative pain and opioid consumption in major abdominal surgery. Dexmedetomidine, known for its sedative, analgesic, and opioid-sparing properties, is increasingly used as an adjunct to anesthesia. Analyzing existing literature, the review found that dexmedetomidine administration alongside general anesthesia significantly improves postoperative pain management and reduces opioid consumption. Patients receiving dexmedetomidine reported decreased postoperative pain ratings and required fewer opioids during the recovery phase. Additionally, intraoperative dexmedetomidine use correlated with reduced postoperative pain severity and increased patient satisfaction compared to control groups. However, potential side effects such as bradycardia and hypotension were noted, necessitating careful patient selection and monitoring to mitigate risks. In conclusion, dexmedetomidine offers promising outcomes as an adjuvant for major abdominal surgery by providing effective analgesia while reducing reliance on opioids. Further research is warranted to optimize dosing and administration strategies, ensuring the safe and efficacious use of dexmedetomidine in perioperative care.
Ahmad H. Elrefahy (Thu,) studied this question.